Over the last decade, a number of candidate gene association studies has been conducted in cancer patients to assess the role of the ATM rs1801516 gene polymorphism as risk factor for normal tissue complications of radiotherapy, in particular in prostate cancer, however inconsistent results have been reported due to insufficient statistical power of most studies [33, 35–37]. The gene discussed is ATM; the disease is Familial prostate cancer.